{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TKIs",
    "query": {
      "intervention": "TKIs"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 32,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TKIs&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-09T05:56:27.135Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03106779",
      "title": "Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "Asciminib",
          "type": "DRUG"
        },
        {
          "name": "Bosutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 233,
      "start_date": "2017-10-26",
      "completion_date": "2024-12-04",
      "has_results": true,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-09-09T05:56:27.135Z",
      "location_count": 10,
      "location_summary": "Chicago, Illinois • Beech Grove, Indiana • Baltimore, Maryland + 6 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Beech Grove",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03106779"
    },
    {
      "nct_id": "NCT04541407",
      "title": "Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "CNS Progression"
      ],
      "interventions": [
        {
          "name": "Temozolomide plus Osimertinib",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide plus Lorlatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2020-10-29",
      "completion_date": "2022-06-07",
      "has_results": false,
      "last_update_posted_date": "2023-05-16",
      "last_synced_at": "2026-09-09T05:56:27.135Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04541407"
    },
    {
      "nct_id": "NCT07151820",
      "title": "A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Leukemia, Chronic Myeloid"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2546,
      "start_date": "2024-04-08",
      "completion_date": "2024-10-22",
      "has_results": false,
      "last_update_posted_date": "2025-09-03",
      "last_synced_at": "2026-09-09T05:56:27.135Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07151820"
    },
    {
      "nct_id": "NCT06567015",
      "title": "Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer (NSCLC)"
      ],
      "interventions": [
        {
          "name": "STX-241",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pierre Fabre Medicament",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 171,
      "start_date": "2024-09-17",
      "completion_date": "2030-07",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-09-09T05:56:27.135Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee • Houston, Texas",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06567015"
    },
    {
      "nct_id": "NCT03610971",
      "title": "Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Phase Chronic Myeloid Leukemia",
        "Chronic Myeloid Leukemia, Chronic Phase"
      ],
      "interventions": [
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        },
        {
          "name": "BCR-ABL Tyrosine Kinase Inhibitor (TKI)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2019-11-19",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-09-09T05:56:27.135Z",
      "location_count": 8,
      "location_summary": "Tampa, Florida • Atlanta, Georgia • Montvale, New Jersey + 5 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03610971"
    },
    {
      "nct_id": "NCT04739358",
      "title": "CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Non-Small Cell Lung Cancer With MET Mutations"
      ],
      "interventions": [
        {
          "name": "Tepotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Criterium, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2022-05-25",
      "completion_date": "2023-06-23",
      "has_results": false,
      "last_update_posted_date": "2023-10-18",
      "last_synced_at": "2026-09-09T05:56:27.135Z",
      "location_count": 5,
      "location_summary": "Sacramento, California • Aurora, Colorado • Washington D.C., District of Columbia + 2 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04739358"
    },
    {
      "nct_id": "NCT02108964",
      "title": "A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "EGF816",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 225,
      "start_date": "2014-06-06",
      "completion_date": "2023-08-15",
      "has_results": true,
      "last_update_posted_date": "2024-12-11",
      "last_synced_at": "2026-09-09T05:56:27.135Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • New York, New York",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02108964"
    },
    {
      "nct_id": "NCT04634110",
      "title": "Brigatinib Before Brain Irradiation Trial (B3i Trial)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain Metastases",
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Brigatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2020-11-17",
      "completion_date": "2022-04-14",
      "has_results": true,
      "last_update_posted_date": "2022-10-24",
      "last_synced_at": "2026-09-09T05:56:27.135Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Aurora, Colorado • Rochester, Minnesota",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04634110"
    },
    {
      "nct_id": "NCT01657682",
      "title": "A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies"
      ],
      "interventions": [
        {
          "name": "Crenolanib besylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arog Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2012-10",
      "completion_date": "2019-04",
      "has_results": true,
      "last_update_posted_date": "2023-11-30",
      "last_synced_at": "2026-09-09T05:56:27.135Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01657682"
    },
    {
      "nct_id": "NCT02921477",
      "title": "Study for the Use of TKIs for Treatment of Cognitive Decline Due to Degenerative Dementias",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mild Cognitive Impairment",
        "Dementia"
      ],
      "interventions": [
        {
          "name": "bosutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurological Associates of West Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "45 Years to 89 Years"
      },
      "enrollment_count": 150,
      "start_date": "2016-09",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2022-09-28",
      "last_synced_at": "2026-09-09T05:56:27.135Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02921477"
    }
  ]
}